The mean physical component summary scores were 68.2 versus 73 for enrolment versus control, (p=0.12), 68.2 versus 77 for enrolment versus crossover, (p=0.01), and 68.2 versus 71 for enrolment versus completion, (p=0.18).
The mental component summary score of the SF-36 remained unchanged throughout the study duration.
The sexual function domain of the EPIC was worse when the baseline scores were compared with completion scores, (p=0.05). However, the patients reported no significant bother from this decrease in sexual function at enrolment (3.3) versus completion (3.2), (p=0.89).
The hormonal domain score was stable at enrolment (82.6) versus completion (79.5), (p=0.41).
A significant increase in patient satisfaction was reported at crossover and maintained throughout study completion, (p=0.03).
The median duration of castrate testosterone was 5.5 months (mean: 6, range: 3.5 - 10).
The forward stepwise regression showed that a longer duration of castrate testosterone was significantly correlated with lower pretreatment serum testosterone and smaller body mass index.